Nile Pharmaceuticals results, Q3 2022
Net profit, assets, equity and cash flow for Q3 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit27.21 millionEGP
Total assets780 millionEGP
Shareholders' equity408 millionEGP
Operating cash flow4.07 millionEGP
In short
- Nile Pharmaceuticals's net profit for Q3 2022 was about 27.21 million EGP.
- Total assets at the end of Q3 2022 were about 780 million EGP, and shareholders' equity about 408 million EGP.
- Operating cash flow for Q3 2022 was positive at 4.07 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit27.21 million——
Gross profit70.5 million——
Total assets780 million——
Total liabilities372 million——
Shareholders' equity408 million——
Total liabilities and equity780 million——
Operating cash flow4.07 million——
Investing cash flow-2.51 million——
Financing cash flow9.27 million——
Net change in cash10.83 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy